USPTO Patent Grant for Chimeric Antigen and T Cell Receptors

The USPTO has granted patent US12583923B2 to Kite Pharma, Inc. for chimeric antigen and T cell receptors and methods of use. The patent covers novel CAR or TCR constructs designed for potential cancer treatment applications.

USPTO Patent Grant: Lewy Body Disorder Treatment

The USPTO has granted a patent (US12583894B2) to the University of Florida Research Foundation, Inc. for methods of treating Lewy body disorders. The patent covers administering a T cell specific for an alpha-synuclein mutant to reduce Lewy bodies in the central nervous system.

USPTO Patent Grant: Liquid Extraction from Solid Phase

The USPTO has granted patent US12582924B2 for a method of obtaining liquid from a solid phase, particularly useful for nucleic acid extractions. The patent, assigned to Cambridge Enterprise Limited, describes an improved liquid extraction technique that increases recovery compared to existing methods.

USPTO Patent Grant: RNA-based Adjuvant for Vaccines

The USPTO has granted patent US12582711B2 to IMMUNESURE LLC for an RNA-based adjuvant composition designed to enhance immune responses to vaccines and therapeutics. The patent describes antisense inhibitor compositions targeting IL-10 or IL-10RA genes.

USPTO Patent Grant: T-cell responses to cancer antigens

The USPTO has granted patent US12582709B2 to The Regents of the University of California for a novel method of inducing long-lived immune responses to cancer and infectious-disease antigens. The patent covers recombinant polynucleotides and their use in pharmaceutical compositions and host cells.

USPTO Patent US12582708B2: Recombinant Influenza Viruses

The USPTO has granted patent US12582708B2 for a novel recombinant influenza virus engineered to express an interferon-beta gene. This patent, assigned to I.D.BIO., aims to enhance antiviral action by introducing a foreign gene into the NS1 gene of the influenza virus.

USPTO Patent US12582699B2: Lymphocyte Immunotherapy Compositions

The USPTO has granted patent US12582699B2 to the Provincial Health Services Authority for lymphocyte immunotherapy compositions and methods. The patent covers lymphocytes with suppressed autophagy genes, useful for targeting tumor-specific antigens in therapies like CAR-T and TCR-T.

USPTO Patent Grant: Skin Wound Treatment Compositions and Methods

The USPTO has granted patent US12582684B2 to Krystal Biotech, Inc. for compositions and methods related to the treatment of skin wounds, disorders, and diseases. The patent covers polynucleotides designed to enhance specific protein levels for therapeutic relief, particularly for conditions like epidermolysis bullosa.

USPTO Patent Grant: Pharmaceutical Composition for Skin Disease

The USPTO has granted a patent (US12582680B2) to RIKEN for a pharmaceutical composition derived from ampicillin-sensitive bacteria to treat skin diseases. The patent covers bacterial cells, culture supernatants, extracts, and metabolites as active components.

Sumitomo Chemical Patent: Retinal Tissue Production Method

The USPTO has granted Sumitomo Chemical Company, Limited a patent (US12582677B2) for a method of producing retinal tissue. The method involves culturing pluripotent stem cells under specific serum-free and serum-containing conditions. This patent covers methods for producing optic-cup-like structures, retinal pigment epithelium, and retinal layer-specific neural cells.